SCHEMBL314719

SCHEMBL314719

O=C(CCc1cc(I)c(O)c(I)c1)NC(Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 3/20 0.52
NAALAD2 Q9Y3Q0 1/20 0.52
ACE P12821 5/20 0.51
MME P08473 4/20 0.48
PCNA P12004 2/20 0.48
CPA1 P15085 1/20 0.48
ACE2 Q9BYF1 1/20 0.48
ITGB3 P05106 1/20 0.47
ITGA2B P08514 1/20 0.47
GRIA1 P42261 1/20 0.46
EPHX2 P34913 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4147877 0.88 NAALAD2 (0.61) FOLH1NAALAD2ACEMMECPA1
SCHEMBL4147882 0.88 NAALAD2 (0.61) FOLH1NAALAD2ACEMMECPA1
SCHEMBL13123764 0.85 ALDH1A1 (0.48) PCNA
SCHEMBL31072235 0.85 ALDH1A1 (0.48) PCNA
SCHEMBL30081063 0.84 ACE (0.56) FOLH1NAALAD2ACEMMECPA1
SCHEMBL30081065 0.84 ACE (0.56) FOLH1NAALAD2ACEMMECPA1
SCHEMBL4147927 0.84 ITGB3 (0.62) FOLH1NAALAD2ACEMMEITGB3
SCHEMBL4147924 0.84 ITGB3 (0.62) FOLH1NAALAD2ACEMMEITGB3
SCHEMBL4147417 0.84 ITGB3 (0.62) FOLH1NAALAD2ACEMMEITGB3
SCHEMBL4147413 0.84 ITGB3 (0.62) FOLH1NAALAD2ACEMMEITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10888361-B2 Devices, compositions and methods for bone and tissue augmentation REVA Medical LLC (US) 2021-01-12 US disclosed
US-20190117281-A1 DEVICES, COMPOSITIONS AND METHODS FOR BONE AND TISSUE AUGMENTATION REVA MEDICAL, LLC 2019-04-25 US disclosed
US-9782523-B2 Side-chain crystallizable polymers for medical applications REVA MEDICAL, INC. (US) 2017-10-10 US disclosed
EP-2446907-A1 Side-chain crystallizable polymers for medical applications Reva Medical, Inc. (US) 2012-05-02 EP disclosed
US-8133959-B2 Side-chain crystallizable polymers for medical applications REVA MEDICAL, INC. (US) 2012-03-13 US disclosed
US-8124700-B2 Side-chain crystallizable polymers for medical applications REVA MEDICAL, INC. (US) 2012-02-28 US disclosed
US-20110213456-A1 SIDE-CHAIN CRYSTALLIZABLE POLYMERS FOR MEDICAL APPLICATIONS REVA MEDICAL, INC. (US) 2011-09-01 US disclosed
US-20110213090-A1 SIDE-CHAIN CRYSTALLIZABLE POLYMERS FOR MEDICAL APPLICATIONS REVA MEDICAL, INC. (US) 2011-09-01 US disclosed
US-20110212050-A1 SIDE-CHAIN CRYSTALLIZABLE POLYMERS FOR MEDICAL APPLICATIONS REVA MEDICAL, INC. (US) 2011-09-01 US disclosed
US-7939611-B2 Side-chain crystallizable polymers for medical applications REVA MEDICAL, INC. (US) 2011-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10888361-B2 Devices, compositions and methods for bone and tissue augmentation BMP2, COL2A1, MATR3 FOLH1 2389/4885NAALAD2 3165/4885ACE 1668/4885
US-20110212050-A1 SIDE-CHAIN CRYSTALLIZABLE POLYMERS FOR MEDICAL APPLICATIONS IRS1, INSRR, LCP1 FOLH1 2176/4885NAALAD2 4213/4885ACE 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.